Thank you for sharing!

Your article was successfully shared with the contacts you provided.
With its stock suffering on Wall Street’s aversion to money losing biotech companies, San Diego, Calif.-based Illumina Inc. announced a stockholders’ rights plan May 4 designed to stave off unsolicited bargain hunters. As is typical of poison pill provisions, the plan would take effect once any one party’s interest crossed a certain ownership threshold, in this case 15 percent. At that point, current shareholders would be able to purchase additional shares at a steep discount, effectively ballooning the total number of outstanding shares and the price a hostile bidder would have to pay. Illumina CFO Tim Kish classified the move as a good way to maintain long-term value for shareholders, but would not comment on whether any companies have expressed interest in acquiring Illumina. The company has developed a fiber optic array technology that allows for genetic analysis testing of thousands of discreet microscopic samples each affixed to the ends of individual fibers in a bundle, thus allowing for more effective and dense testing of genetic products. Through March 31, the company had $113.6 million in cash. When its stock bottomed out at $5.69 on April 6, the company’s valuation was dragged down to $166.4 million. Given the company’s proprietary technology and its healthy pile of cash, the company that just months earlier boasted a market cap north of $1.5 billion found itself as an attractive target. Illumina reported a loss of $4.9 million on $600,000 in sales for the first quarter 2001. “They realized their technology would be going for a low price, so they moved to protect it,” said Lawrence Neibor, an analyst with Robert W Baird Co. in Milwaukee, Wisc. He doesn’t expect the company to turn a profit until 2003. Before it went public, the company received more than $36 million in venture funding from the Tisch Family Fund, Lombard Odier & Cie, State Farm Automobile Insurance Company, Chase Capital Partners, PE Corp., The Dow Chemical Co., Chevron Technology Ventures, Venrock Associates, ARCH Venture Partners, CW Group and Tredegar Investments. The company sold 6 million shares at $16 to raise $96 million in its initial public offering in July 2000. Within three months, the company’s stock topped $50 per share before beginning its descent to a low of $5.69 in early April. But Illumina is not the only young biotech company that has taken a shellacking from Wall Street. Aclara Biosciences Inc., a Mountain View, Calif., maker of biochemical analysis tools, has seen its shares drop from a high in July of $66 to $5.45 Friday. Genomica Corp. a Boulder, Colo., developer of drug development and discovery software that went public in October 2000, has fallen from its high of $23.38 to $4.05. Illumina shares closed down 2 cents to $8.98 Friday. Copyright (c)2001 TDD, LLC. All rights reserved.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.